• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

软脑膜转移时间对EGFR突变型肺腺癌患者预后的影响及脑脊液中可检测到EGFR突变的预测因素。

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of -Mutant Lung Adenocarcinoma Patients and Predictors of Detectable Mutations in Cerebrospinal Fluid.

作者信息

Liao Pei-Ya, Ou Wei-Fan, Su Kang-Yi, Sun Ming-Hsi, Huang Chih-Mei, Chen Kun-Chieh, Hsu Kuo-Hsuan, Yu Sung-Liang, Huang Yen-Hsiang, Tseng Jeng-Sen, Yang Tsung-Ying, Chang Gee-Chen

机构信息

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.

Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.

出版信息

Cancers (Basel). 2022 Jun 7;14(12):2824. doi: 10.3390/cancers14122824.

DOI:10.3390/cancers14122824
PMID:35740489
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9221267/
Abstract

BACKGROUND

We aim to evaluate the influence of the timing of leptomeningeal metastasis (LM) occurrence on the outcome of -mutant lung adenocarcinoma and to explore the predictors of detectable mutation in the cerebrospinal fluid (CSF).

METHODS

-mutant lung adenocarcinoma patients with cytologically confirmed LM were included for analysis. mutation in CSF was detected by MALDI-TOF MS plus PNA.

RESULTS

A total of 43 patients was analyzed. Of them, 8 (18.6%) were diagnosed with LM prior to first-line EGFR-TKI treatment (early onset), while 35 patients (81.4%) developed LM after first-line EGFR-TKI treatment (late onset). Multivariate analysis suggested that both late-onset LM (aHR 0.31 (95% CI 0.10-0.94), = 0.038) and a history of third-generation EGFR-TKI treatment (aHR 0.24 (95% CI 0.09-0.67), = 0.006) independently predicted a favorable outcome. mutation detection sensitivity in CSF was 81.4%. The radiological burden of LM significantly correlated with CSF tumor cell counts ( = 0.013) with higher CSF tumor cell counts predicting a higher detection sensitivity of mutation ( = 0.042).

CONCLUSIONS

Early onset LM was an independently poor prognostic factor. A higher radiological severity score of LM could predict higher tumor cell counts in CSF, which in turn were associated with a higher detection rate of mutation.

摘要

背景

我们旨在评估软脑膜转移(LM)发生时间对EGFR突变型肺腺癌预后的影响,并探索脑脊液(CSF)中可检测到EGFR突变的预测因素。

方法

纳入经细胞学确诊为LM的EGFR突变型肺腺癌患者进行分析。采用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)加肽核酸(PNA)检测CSF中的EGFR突变。

结果

共分析43例患者。其中,8例(18.6%)在一线EGFR-TKI治疗前被诊断为LM(早发),而35例患者(81.4%)在一线EGFR-TKI治疗后发生LM(晚发)。多因素分析表明,晚发LM(调整后风险比[aHR] 0.31[95%置信区间(CI)0.10 - 0.94],P = 0.038)和第三代EGFR-TKI治疗史(aHR 0.24[95% CI 0.09 - 0.67],P = 0.006)均独立预测良好预后。CSF中EGFR突变检测敏感性为81.4%。LM的影像学负担与CSF肿瘤细胞计数显著相关(P = 0.013),CSF肿瘤细胞计数越高,EGFR突变检测敏感性越高(P = 0.042)。

结论

早发LM是独立的不良预后因素。LM较高的影像学严重程度评分可预测CSF中较高的肿瘤细胞计数,而这又与EGFR突变的较高检出率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/4fe28302ca50/cancers-14-02824-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/9c772e5f7eaa/cancers-14-02824-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/7e10fafd840a/cancers-14-02824-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/4fe28302ca50/cancers-14-02824-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/9c772e5f7eaa/cancers-14-02824-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/7e10fafd840a/cancers-14-02824-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c64/9221267/4fe28302ca50/cancers-14-02824-g003.jpg

相似文献

1
Influence of the Timing of Leptomeningeal Metastasis on the Outcome of -Mutant Lung Adenocarcinoma Patients and Predictors of Detectable Mutations in Cerebrospinal Fluid.软脑膜转移时间对EGFR突变型肺腺癌患者预后的影响及脑脊液中可检测到EGFR突变的预测因素。
Cancers (Basel). 2022 Jun 7;14(12):2824. doi: 10.3390/cancers14122824.
2
Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.采用下一代测序技术检测肺腺癌软脑膜转移患者脑脊液中的基因改变。
BMC Cancer. 2022 May 25;22(1):580. doi: 10.1186/s12885-022-09597-y.
3
Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.肺腺癌脑膜转移患者脑脊液中表皮生长因子受体突变检测。
Cancer Biother Radiopharm. 2019 Mar;34(2):128-133. doi: 10.1089/cbr.2018.2580. Epub 2018 Nov 16.
4
Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.脑脊液游离 DNA 在 EGFR 突变型非小细胞肺癌伴脑膜转移患者中的应用。
Target Oncol. 2021 Mar;16(2):207-214. doi: 10.1007/s11523-021-00791-9. Epub 2021 Feb 10.
5
Cell-free DNA from cerebrospinal fluid can be used to detect the mutation status of lung adenocarcinoma patients with central nervous system metastasis.脑脊液中的游离DNA可用于检测发生中枢神经系统转移的肺腺癌患者的突变状态。
Transl Lung Cancer Res. 2021 Feb;10(2):914-925. doi: 10.21037/tlcr-21-62.
6
Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.脑脊液分子特征对非小细胞肺癌脑膜转移患者的预后意义。
Thorac Cancer. 2019 Aug;10(8):1673-1682. doi: 10.1111/1759-7714.13123. Epub 2019 Jul 10.
7
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.脑脊液游离 DNA 中的独特基因突变谱在 EGFR 突变型非小细胞肺癌脑膜转移中的作用:一种新的液体活检方法。
Ann Oncol. 2018 Apr 1;29(4):945-952. doi: 10.1093/annonc/mdy009.
8
[Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].[不同种类酪氨酸激酶抑制剂治疗表皮生长因子受体突变的非小细胞肺癌合并软脑膜转移患者的生存分析]
Zhonghua Yi Xue Za Zhi. 2022 Feb 15;102(6):399-405. doi: 10.3760/cma.j.cn112137-20211009-02231.
9
Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.前瞻性研究揭示了脑膜转移反应的预后意义和基于脑脊液的液体活检的临床价值。
Lung Cancer. 2018 Nov;125:142-149. doi: 10.1016/j.lungcan.2018.08.017. Epub 2018 Sep 17.
10
Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.晚期非小细胞肺癌经第一代 EGFR TKI 治疗有效后发生脑膜转移。
Lung Cancer. 2019 Jan;127:1-5. doi: 10.1016/j.lungcan.2018.11.022. Epub 2018 Nov 20.

引用本文的文献

1
Treatment Advances in Lung Cancer with Leptomeningeal Metastasis.肺癌脑膜转移的治疗进展。
Curr Cancer Drug Targets. 2024;24(9):910-919. doi: 10.2174/0115680096276133231201061114.

本文引用的文献

1
Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis.脑脊液游离DNA的独特基因组改变对于非小细胞肺癌软脑膜转移的靶向治疗至关重要。
Genomics. 2021 Nov 15. doi: 10.1016/j.ygeno.2021.11.015.
2
Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status.奥希替尼用于治疗伴有软脑膜转移且T790M状态不同的表皮生长因子受体突变的非小细胞肺癌患者。
Ann Transl Med. 2021 Jun;9(11):937. doi: 10.21037/atm-21-1249.
3
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
奥希替尼预防晚期 EGFR 突变型非小细胞肺癌脑膜转移的疗效:一项倾向评分匹配回顾性研究。
BMC Cancer. 2021 Jul 30;21(1):873. doi: 10.1186/s12885-021-08581-2.
4
Cell-free DNA from cerebrospinal fluid can be used to detect the mutation status of lung adenocarcinoma patients with central nervous system metastasis.脑脊液中的游离DNA可用于检测发生中枢神经系统转移的肺腺癌患者的突变状态。
Transl Lung Cancer Res. 2021 Feb;10(2):914-925. doi: 10.21037/tlcr-21-62.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.非小细胞肺癌中的脑膜转移:有无驱动基因突变的 NSCLC 的最佳全身治疗策略。
Curr Treat Options Oncol. 2020 Jul 28;21(9):72. doi: 10.1007/s11864-020-00759-3.
7
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.奥希替尼改善了不论 T790M 突变状态如何的伴有脑膜转移的 EGFR 突变型 NSCLC 患者的总生存期。
J Thorac Oncol. 2020 Nov;15(11):1758-1766. doi: 10.1016/j.jtho.2020.06.018. Epub 2020 Jul 9.
8
A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer.对非小细胞肺癌软脑膜转移患者疾病负担的回顾性定量评估。
Neuro Oncol. 2020 May 15;22(5):675-683. doi: 10.1093/neuonc/noz208.
9
Precision Management of Advanced Non-Small Cell Lung Cancer.晚期非小细胞肺癌的精准管理。
Annu Rev Med. 2020 Jan 27;71:117-136. doi: 10.1146/annurev-med-051718-013524.
10
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.奥希替尼治疗伴有 EGFR T790M 阳性的晚期 NSCLC 患者的脑膜转移:AURA 脑膜转移分析。
J Thorac Oncol. 2020 Apr;15(4):637-648. doi: 10.1016/j.jtho.2019.12.113. Epub 2019 Dec 27.